Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Furthermore, the prevalence of scoliosis of type IV OI children (19%) was obviously higher than type I OI children (0%) (P < 0.05) (Table 2).The characteristics and serum DKK1 level of different clinical types of OI patients and healthy controlsOI type I (n = 34)OI type III (n = 12)OI type IV (n = 16)Control (n = 29)P valueGender (male/female)22/1211/1j13/313/160.013Age, years10.00 (7.00, 12.00)4.75 (3.00, 12.50)8.50 (4.25, 11.00)8.00 (5.50, 10.00)0.272Height, cm135.63 ± 20.90117.96 ± 26.34122.34 ± 24.73129.98 ± 18.610.061Height Z score− 0.12 ± 1.00− 0.91 ± 1.62j− 0.95 ± 1.69f0.48 ± 1.230.003Weight, kg35.00 (22.25, 46.25)17.00 (13.63, 48.75)26.00 (15.25, 40.63)25.00 (19.50, 31.00)0.205Weight Z score0.16 (-0.59, 1.04)− 0.33 (− 0.75, 0.81)0.06 (− 1.16, 1.18)− 0.14 (− 0.80, 0.79)0.756Ca, mmol/L2.48 ± 0.072.45 ± 0.062.50 ± 0.102.45 ± 0.080.221P, mmol/L1.72 ± 0.181.65 ± 0.231.65 ± 0.211.66 ± 0.160.586ALP, U/L319.32 ± 87.25e295.42 ± 69.88336.56 ± 127.30f229.58 ± 66.300.000ALT, U/L13.50 (10.75, 195.00)11.50 (10.00, 21.50)19.00 (11.25, 20.00)15.00 (10.00, 17.00)0.445Cr, μmol/L37.50 (33.00, 43.00)33.00 (27.50, 37.75)j33.50 (27.50, 39.75)k45.00 (33.00, 46.00)0.007PTH, pg/mL27.95 (20.25, 37.10)b20.20 (17.83, 34.18)20.85 (17.75, 25.85)17.30 (15.00, 22.30)0.000P1NP, ng/mL403.00 (299.00, 577.00)410.00 (295.00, 758.00)280.00 (228.70, 506.93)423.00 (343.00, 531.00)0.248β-CTX, ng/mL1.23 (1.05, 1.62)a1.11 (0.90, 1.30)0.80 (0.66, 0.87)k1.16 (0.97, 1.41)0.00025OHD, ng/mL21.90 (17.25, 28.00)26.20 (16.25, 58.70)21.95 (15.70, 42.05)23.50 (19.50, 28.65)0.700LS BMD, g/cm20.55 (0.48, 0.73)g, h0.41 (0.33, 0.50)0.37 (0.33, 0.56): 0.001LS BMD Z-score− 0.93 ± 1.26 g, h− 2.31 ± 1.54− 2.31 ± 1.95 to 0.003FN BMD, g/cm20.54 ± 0.13 g,h0.42 ± 0.120.43 ± 0.18 to 0.013FN BMD Z-score− 2.16 (− 3.45, -1.51)g, h− 4.01 (− 5.02, − 2.06)− 3.45 (− 5.25, − 2.25): 0.027Troch BMD, g/cm20.41 ± 0.100.35 ± 0.120.34 ± 0.16 to 0.104TH BMD, g/cm20.54 ± 0.12g,h0.45 ± 0.120.46 ± 0.18 to 0.048OPG, ng/mL0.71 (0.46, 1.14)0.61 (0.48, 1.09)0.55 (0.29, 0.99)0.74 (0.52, 1.35)0.314Sclerostin, pmol/L25.12 (19.65, 32.46)c17.74 (14.00, 22.61)l18.49 (14.46, 20.52)m30.41 (22.51, 34.00)0.000DKK1, ng/mL5.20 (4.61, 6.19) e5.67 (4.29, 6.42)j4.80 (4.06, 6.48)4.08 (3.59, 4.92)0.003Blue sclera, n281213: 0.340Dentinogenesis imperfecta, n322: 0.656Ligament laxity, n1456: 0.965Hearing abnormality, n001: 0.452Age at first fracture, years3.00 (1.00, 5.00)1.75 (1.00, 4.50)2.00 (1.05, 5.00): 0.534Peripheral fracture, n301216: 0.298Number of peripheral fracture3.00 (1.00, 4.50)4.50 (3.00, 6.00)3 (2.25, 5.00): 0.090Frequency of peripheral fracture per year0.64 (0.30, 1.00)c, d1.00 (1.00, 2.88)1.16 (0.85, 2.30): 0.000VCF, n1138: 0.334Wheelchair dependence, n744: 0.619Long bone deformity, n1g, h95: 0.000Scoliosis, n0h03: 0.021Ribcage deformity, n222: 0.449The results for normally distributed data were presented as the mean ± SDNonnormally distributed data were presented as medians (quartiles)Categorical data were presented as numbersBold values indicated significant differences among 3 or 4 groupsOI osteogenesis imperfecta, Ca calcium, P phosphorus, ALP alkaline phosphatase, ALT glutamic-pyruvic transaminase, Cr creatinine, PTH parathyroid hormone, P1NP procollagen type 1 N-peptide, β-CTX β-C-terminal telopeptide of type 1 collagen, 25OHD 25-hydroxyvitamin D, LS lumbar spine, FN femoral neck, TH total hip, BMD bone mineral density, OPG Osteoprotegerin, VCF vertebral compression fractureaP < 0.001 for OI-I vs.
Source: Basic characteristics of OI children. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
A cohort of pediatric OI patients and age-matched healthy children were enrolled.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Correlation of serum DKK1 level with skeletal phenotype in children with osteogenesis imperfecta
Study design awaiting verification · Journal of Endocrinological Investigation · 2024
Original publication title
Correlation of serum DKK1 level with skeletal phenotype in children with osteogenesis imperfecta
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
We aim to detect serum DKK1 level of pediatric patients with OI and to analyze its relationship with the genotype and phenotype of OI patients.
Source: PurposeAbstract: What methods does the paper describe?
A cohort of pediatric OI patients and age-matched healthy children were enrolled. Serum levels of DKK1 and bone turnover biomarkers were measured by enzyme-linked immunosorbent assay. Bone mineral density (BMD) was measured by Dual-energy X-ray absorptiometry. Pathogenic mutations of OI were detected by next-generation sequencing and confirmed by Sanger sequencing.
Source: MethodsAbstract: Results
A total of 62 OI children with mean age of 9.50 (4.86, 12.00) years and 29 healthy children were included in this study. The serum DKK1 concentration in OI children was significantly higher than that in healthy children [5.20 (4.54, 6.32) and 4.08 (3.59, 4.92) ng/mL, P < 0.001]. The serum DKK1 concentration in OI children was negatively correlated with height (r = − 0.282), height Z score (r = − 0.292), ALP concentration (r = − 0.304), lumbar BMD (r = − 0.276), BMD Z score of the lumbar spine and femoral neck (r = − 0.32; r = − 0.27) (all P < 0.05).
No significant difference in serum DKK1 concentration was found between OI patients with and without vertebral compression fractures. In patients with spinal deformity (22/62), serum DKK1 concentration was positively correlated with SDI (r = 0.480, P < 0.05). No significant correlation was observed between serum DKK1 concentration and the annual incidence of peripheral fractures, genotype and types of collagen changes in OI children.
Source: ResultsAbstract: Conclusion
The serum DKK1 level was not only significantly elevated in OI children, but also closely correlated to their skeletal phenotype, suggesting that DKK1 may become a new biomarker and a potential therapeutic target of OI.
Source: ConclusionAuthors’ abstract
Purpose
We aim to detect serum DKK1 level of pediatric patients with OI and to analyze its relationship with the genotype and phenotype of OI patients.
Methods
A cohort of pediatric OI patients and age-matched healthy children were enrolled. Serum levels of DKK1 and bone turnover biomarkers were measured by enzyme-linked immunosorbent assay. Bone mineral density (BMD) was measured by Dual-energy X-ray absorptiometry. Pathogenic mutations of OI were detected by next-generation sequencing and confirmed by Sanger sequencing.
Results
A total of 62 OI children with mean age of 9.50 (4.86, 12.00) years and 29 healthy children were included in this study. The serum DKK1 concentration in OI children was significantly higher than that in healthy children [5.20 (4.54, 6.32) and 4.08 (3.59, 4.92) ng/mL, P < 0.001]. The serum DKK1 concentration in OI children was negatively correlated with height (r = − 0.282), height Z score (r = − 0.292), ALP concentration (r = − 0.304), lumbar BMD (r = − 0.276), BMD Z score of the lumbar spine and femoral neck (r = − 0.32; r = − 0.27) (all P < 0.05).
No significant difference in serum DKK1 concentration was found between OI patients with and without vertebral compression fractures. In patients with spinal deformity (22/62), serum DKK1 concentration was positively correlated with SDI (r = 0.480, P < 0.05). No significant correlation was observed between serum DKK1 concentration and the annual incidence of peripheral fractures, genotype and types of collagen changes in OI children.
Conclusion
The serum DKK1 level was not only significantly elevated in OI children, but also closely correlated to their skeletal phenotype, suggesting that DKK1 may become a new biomarker and a potential therapeutic target of OI.
Supplementary Information
The online version contains supplementary material available at 10.1007/s40618-024-02380-9.
Publication and source details
Original title: Correlation of serum DKK1 level with skeletal phenotype in children with osteogenesis imperfecta
Y. Wang; J. Hu; L. Sun; B. Zhou; X. Lin; Q. Zhang; O. Wang; Y. Jiang; W. Xia; X. Xing; M. Li
Journal of Endocrinological Investigation · 2024
© The Author(s) 20242024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.National Key R&D Program of China2021YFC2501700Li M. http://dx.doi.org/10.13039/501100001809National Natural Science Foundation of China8207090882370894Li M. CAMS Innovation Fund for Medical Sciences (CIFMS) 2021-I2M-1-051Li M. National High-Level Hospital Clinical Research Funding2022-PUMCH-B-014Li M.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T11:32:30.009113+00:00
DOI: 10.1007/s40618-024-02380-9 · PMC11473575